Not yet recruitingPhase 2NCT07756736
Psilocybin Therapy for Methamphetamine Use Disorder and HIV
The goal of this clinical trial is to learn whether it is possible to use psilocybin in combination with motivational support therapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in people with HIV who are seeking to stop using methamphetamine. (The sponsor's summary, shortened.)
Eligibility and contacts on ClinicalTrials.govThe registry record
- Status
- Not yet recruiting
- Phase
- Phase 2
- Conditions
- Methamphetamine Use Disorder; Human Immunodeficiency Virus (HIV)
- Intervention
- Psilocybin 5 mg; Psilocybin 25 mg; Motivational Support
- Sponsor
- Nicky Mehtani, MD, MPH
- Ages
- 25 Years to 64 Years
- Sex
- All
- Healthy volunteers
- No
- Enrolment
- 30 people (planned)
- Start
- November 2026
- Primary completion
- April 2029
- Registry last updated
- 11 August 2026
Sites (1)
- UCSF at Zuckerberg San Francisco General Hospital, San Francisco, California, United States
How joining a trial works
- Free to take part
- Trials generally cost participants nothing for the study drug and the study visits, and some pay for travel or time. Check what a study covers on its registry page.
- Screened first
- Every study screens volunteers with questionnaires, medical history and often a physical and psychiatric check. Many people who apply are not enrolled.
- Eligibility is strict
- Common exclusions include a personal or family history of psychosis or bipolar disorder, some heart conditions, pregnancy and certain medications, which you may be asked to stop under medical supervision. Never stop a medication on your own to qualify.
- You may get a placebo
- Many trials compare psilocybin with a placebo or a low dose, and you may not be told which you had until the study ends.
- Contact the study team through the registry
- Each registry record lists the study contacts and sites. We do not republish personal emails or phone numbers; use the link on each trial page.
- Not medical advice
- This is a list of registry records, not a recommendation. Talk to your doctor before applying. Disclaimer · Safety and medications
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine, read 28 October 2026. Filter: overall status RECRUITING or NOT_YET_RECRUITING; an intervention named psilocybin, psilocin, COMP360 or CYB003. Refreshed weekly; a study's own registry page is always the current record.
Record read from ClinicalTrials.gov API v2, U.S. National Library of Medicine on 28 October 2026. All psilocybin trials